secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001437749-26-015621
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotech Q1 net loss $3.8M; raises 2026 revenue and net income guidance on NERLYNX demand
--------------------------------------------------------------------------------

- Q1 product revenue $42.0M vs $43.1M YoY; GAAP net loss $3.8M ($0.07/share) vs net income $3.0M.
- Non-GAAP adjusted net loss $1.9M ($0.04/share) vs adjusted net income $5.0M ($0.10) YoY.
- FY 2026 guidance raised: net product revenue $202-206M (prior $194-198M); net income $16-19M (prior $10-13M).
- Debt fully repaid on May 4, 2026; cash & securities $101.5M at March 31, 2026, up from $97.5M.
- Second-quarter Q2 2026 net product revenue guidance $50-52M, net income $2-4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774926015621/0001437749-26-015621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774926015621/pbyi20260327_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer